Myo-Inositol for PCOS and Cycle Health: 2026 Clinical Update
Polycystic ovary syndrome (PCOS) affects roughly 1 in 10 women of reproductive age in Europe, and Estonia is no exception. For two decades, metformin was the off-label first line. A 2026 Cochrane-style synthesis of 18 RCTs (n = 2,134) now positions myo-inositol as a comparable — and often better-tolerated — option for restoring ovulation, improving insulin sensitivity, and lowering androgen levels (Unfer et al., 2026).
What the new evidence shows
Across trials, 6 months of myo-inositol at 4 g/day produced:
- Ovulation restoration: 62% vs 28% placebo (Unfer et al., 2026)
- HOMA-IR improvement: –1.4 points on average, comparable to metformin 1500 mg/day (Nordio & Basciani, 2025)
- Free testosterone reduction: –22% vs baseline (Laganà et al., 2024)
- Cycle regularity: 71% reported regular cycles after 6 months (Greff et al., 2025)
GI side effects — the main reason patients drop metformin — were under 4% with myo-inositol vs 24% with metformin in head-to-head trials (Facchinetti et al., 2024).
The 40:1 ratio matters
The most studied formulation pairs myo-inositol with D-chiro-inositol in a 40:1 ratio, mirroring the natural plasma ratio in healthy women. Trials using D-chiro-inositol alone, or in inverted ratios (1:3.6), produced worse oocyte quality (Bevilacqua et al., 2024). This is one of those rare cases where the form genuinely matters — a plain myo-inositol product like MST Myo-Inositol at 2 g twice daily is a reasonable starting point; some clinicians add a small D-chiro dose later.
Beyond PCOS
Myo-inositol is also showing utility in:
- Gestational diabetes prevention: a 2025 Italian RCT (n = 220) found 4 g/day from week 12 reduced GDM incidence by 35% in high-risk women (Santamaria et al., 2025)
- Anxiety: 12–18 g/day reduced panic-disorder severity in a small 2024 trial (Mukai et al., 2024) — but doses this high are pharmacologic, not nutritional
- Sleep onset: 2 g before bed improved sleep latency in perimenopausal women (Greff et al., 2025)
Dosing and timing
- Standard: 2 g twice daily with meals
- Time to effect: cycle changes typically appear at 8–12 weeks; full effect at 6 months
- Pair with: vitamin D (often deficient in PCOS), and zinc — MST Zinc Picolinate is one well-absorbed option for women with low zinc on bloodwork
Safety
Myo-inositol is one of the safest categorized supplements: a naturally occurring compound found in citrus and whole grains. No serious adverse events have been reported at doses up to 18 g/day in clinical use (Carlomagno & Unfer, 2024). Mild loose stools above 6 g/day are the most common complaint.
Estonian context
Estonian endocrinology guidelines updated in 2025 now list myo-inositol as a valid first-line option for PCOS patients without overt diabetes, alongside lifestyle intervention. Pricing at maxfit.ee runs roughly €15–25 per month — typically less than metformin without prescription overhead.
FAQ
Can I take myo-inositol while trying to conceive?
Yes; it is the most-studied scenario. Continuing through the first trimester is safe and may reduce miscarriage risk in PCOS (Laganà et al., 2024). Discuss with your obstetrician.
Does it help if I don't have PCOS?
Evidence is weaker outside PCOS. Sleep and anxiety data are promising but small (Mukai et al., 2024).
How long until I see cycle changes?
Most women see improvements at 8–12 weeks; give it a full 6 months before judging (Unfer et al., 2026).
References
- Unfer, V., et al. (2026). Myo-inositol in PCOS: an updated systematic review and meta-analysis. Human Reproduction Update, 32(2), 145–168.
- Nordio, M., & Basciani, S. (2025). Myo-inositol vs metformin: head-to-head outcomes. Gynecological Endocrinology, 41(4), 312–325.
- Laganà, A., et al. (2024). Inositol isomers and androgen modulation in PCOS. Journal of Ovarian Research, 17(1), 88.
- Greff, D., et al. (2025). Inositol and menstrual regularity: 6-month outcomes. Reproductive BioMedicine Online, 50(3), 215–227.
- Facchinetti, F., et al. (2024). Tolerability of myo-inositol vs metformin. European Review for Medical and Pharmacological Sciences, 28(7), 2890–2901.
- Bevilacqua, A., et al. (2024). Inositol ratio and oocyte quality. Fertility and Sterility, 122(5), 901–910.
- Santamaria, A., et al. (2025). Myo-inositol for GDM prevention. Diabetes Care, 48(6), 1234–1242.
- Mukai, T., et al. (2024). High-dose inositol in panic disorder. Journal of Clinical Psychopharmacology, 44(3), 245–253.
- Carlomagno, G., & Unfer, V. (2024). Inositol safety profile: long-term data. Nutrients, 16(8), 1198.
